Updates in MDS: A Special Edition on Higher-risk Disease

Updates in MDS: A Special Edition on Higher-risk Disease
Updates in MDS: A Special Edition on Higher-risk Disease
CME, CPE
Mikkael S. Sekeres, MD, MS
Release Date: April 21, 2021
Expiration Date: April 21, 2022

In this activity, Dr. Sekeres will discuss the current and future treatment landscape for higher-risk MDS. He will provide advice for distinguishing higher-risk MDS from lower-risk MDS, review appropriate treatment goals, and outline current treatment algorithms for higher-risk disease. He will also outline exciting advances in the treatment and management of higher-risk MDS, including a review of the data on the NEDD8 inhibitor pevonedistat, APR 246 targeting TP53-mutations and novel combinations.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
Begin, Earn CreditView Only, No CreditGet Certificate